Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

More documents

Recommendations

Info

4Annual Report on Lymphatic Filariasis 2003ANNEXESAnnex 1 Reports of major international support and partners ........................................................125Annex 2 Revised annual report form .................................................................................................................................. 131Annex 3List of LF-endemic countries and territoriesby Programme Review Group ..............................................................................................................................143Annex 4 Abbreviations and definitions ............................................................................................................................145Contents
P R O G R A M M E H I G H L I G H T S5IN THE COUNTRIES• In 2003, more than 70 million people in 36 countrieswere given the recommended two-drug, once-yearlytreatment of mass drug administration under the GlobalProgramme to Eliminate Lymphatic Filariasis; thisis almost a 14% increase in the number of people coveredsince 2002. Furthermore, 52 million people inIndia were covered with diethylcarbamazine citrate(DEC) alone.• An at-risk population of 11.2 million people was coveredby a first round of MDA in 2003.• The planned national elimination programmes andrequests for donated drugs from three additional countrieswere examined and approved; they will be implementedin 2004.• GlaxoSmithKline donated 94 million albendazole tabletsto WHO, which were supplied to 34 countries foreither the first or a subsequent round of MDA.• Merck & Co., Inc. donated 65.8 million ivermectin(Mectizan®) tablets, which were supplied to eight countriescovered by the African Programme Review Groupand the Eastern Mediterranean Programme ReviewGroup. Of these, 60.2 million were donated for areasendemic for lymphatic filariasis only and 5.6 millionfor areas where lymphatic filariasis and onchocerciasisare co-endemic.• WHO procured 121 million DEC tablets from prequalifiedmanufacturers and supplied them to 22 countries.• Surveys continued in all countries to complete theinitial assessment and mapping of lymphatic filariasistransmission in implementation units.IN THE REGIONS• All the six regional Programme Review Groups met in2003 and reviewed progress being made by country programmesand approved requests for cost-free supply ofdrugs.• Meetings of lymphatic filariasis elimination programmemanagers were held to enable the managersto share experience and exchange information.• A one-day fundraising workshop was organized followingthe meeting of the Mekong-Plus Regional ProgrammeReview Group and was attended by all thenational programme managers of that region.• A workshop on prevention of disability associated withlymphatic filariasis was organized jointly by the UnitedNations Children’s Fund/United Nations DevelopmentProgramme/World Bank/WHO Special Programmefor Research and Training in Tropical Diseases (TDR)and the WHO Programme for the Elimination of LymphaticFilariasis, in Colombo, Sri Lanka, in November2003. The workshop was attended by participants fromBangladesh, India, Indonesia, Nepal, the Philippines,Sri Lanka, Thailand and Viet Nam.• Training was carried out in all Programme ReviewGroup regions on the interruption of transmission andon disability prevention, as shown in the table below.Annual Report on Lymphatic Filariasis 2003Programme highlights
Page 1 and 2: For further information about lymph
Page 3: WHO/CDS/CPE/CEE/2005.52GlobalProgra
Page 7: 3Report of the Technical Advisory G
Page 11: I N T R O D U C T I O N7This Annual
Page 14 and 15: 10Annual Report on Lymphatic Filari
Page 42 and 43: 38Figure 3.2 Outcomes and planning
Page 59 and 60:
UNITED REPUBLIC OF TANZANIA55Endemi
Page 61 and 62:
ZANZIBAR, UNITED REPUBLIC OF TANZAN
Page 63:
59AMERICAN PROGRAMME REVIEWGROUPAt
Page 66 and 67:
62Figure 3.63 Outcomes and planning
Page 68 and 69:
64Annual Report on Lymphatic Filari
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
82Figure 3.100 Outcomes and plannin
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
100Annual Report on Lymphatic Filar
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
114Figure 3.196 Outcomes and planni
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 127:
C H A P T E R 6FURTHER DOCUMENTATIO
Page 130 and 131:
Page 132 and 133:
Page 135 and 136:
ANNUAL REPORT FOR THE NATIONAL PROG
Page 137 and 138:
1332. PROGRAMME RESOURCES2.1 Please
Page 139 and 140:
1353.3 Interruption of transmission
Page 141 and 142:
1373.3.6a Report of MDA coverage by
Page 143 and 144:
1393.3.7 Surveys in sentinel sites
Page 145 and 146:
1413.3.10 Please attach a map of th
Page 147 and 148:
1434. SERIOUS ADVERSE EXPERIENCES (
Page 149 and 150:
A N N E X E SANNEX 3: LIST OF LF-EN
Page 151 and 152:
147RAPLOARPRGSAESEAROTAG-LFTDRUNDPU
Page 153 and 154:
149Drug administration and monitori
show all

Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?